Five consecutive patients with progressive extracutaneous stage IV mycosis fungoides (MF) were treated with VM 26, 100 mg/m2 i.v., for at least 3 cycles. All patients had been extensively pretreated and in particular with vinca alkaloids. Two partial responses of 5 and 9 + months duration and 1 minimal response of 5 months duration were obtained. Transient myelosuppression was encountered in all patients. These preliminary results should encourage further exploration of VM 26, even in less advanced MF.
Get full access to this article
View all access options for this article.
References
1.
ArgyropoulosC.L.LambergS.I.ClendenningW.E.Preliminary evaluation of 15 chemotherapeutic agents applied topically in the treatment of mycosis fungoides.Cancer Treat. Rep., 63: 619–621, 1979.
2.
BunnP.A.Jr., LambergS.I.: Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas.Cancer Treat. Rep., 63: 725–728, 1979.
MinnaJ.D.RoneigkH.H.Jr., GlatsteinE.: Report of the Committee on Therapy for Mycosis Fungoides and Sézary Syndrome.Cancer Treat. Rep., 63: 729–736, 1979.
5.
RadiceP.A.BunnP.A.Jr., IhdeD.C.: Therapeutic trials with VP-16–213 and VM-26: Active agents in small lung cancer, non-Hodgkin's lymphomas, and other malignancies.Cancer Treat. Rep., 63: 1231–1239, 1979.
